Clinical effect of Qishenhuanwu Capsules on Parkinson’s disease with qi and blood deficiency
WANG Wen1 QIU Zhixin1 ZHENG Jianbiao1 JING Haifang1 WANG Aiqing1 LIU Dongfang1 LI Ning1 WNAG Yingli2
1.The Second Department of Encephalopathy, Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Hebei Province, Changzhou 061000, China;
2.Teaching and Research Section of Internal Medicine, Cangzhou Medical College, Hebei Province, Changzhou 061001, China
Abstract：Objective To explore the clinical effect of Qishenhuanwu Capsules in treating Parkinson’s disease (PD) with Qi and blood deficiency. Methods A total of 100 PD patients with Qi and blood deficiency admitted to Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine from March 2020 to January 2022 were selected and divided into control group (conventional drug treatment, 50 cases) and experimental group (conventional drug treatment combined with Qishenhuanwu Capsules, 50 cases) by random number table method. The two groups were treated for a total of six weeks. The clinical effects, motor and non-motor symptoms before and after treatment, and related laboratory indicators were compared between the two groups. Results The clinical efficacy of the experimental group was better than that of the control group, and the difference was statistically significant (P＜0.05). After treatment, the scores of the Simple Intelligent Mental State Assessment Scale and the Montreal Cognitive Assessment Scale in the two groups were higher than before treatment, while those of the experimental group were higher than those of the control group, and the differences were statistically significant (P＜0.05). After treatment, PD rating scale Ⅲ and PD non-motor symptom questionnaire scores of the two groups were lower than before treatment, and those of the experimental group were lower than the control group, and the differences were statistically significant (P＜0.05). After treatment, serum insulin-like growth factor and β-amyloid 1-42 in two groups were higher than before treatment, while those of the experimental group were higher than those of the control group; homocysteine and C-reactive protein in the two groups were lower than before treatment, while those of the experimental group were lower than those of the control group, and the differences were statistically significant (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion Qishenhuanwu Capsules can effectively improve motor and non-motor symptoms of PD patients with qi and blood deficiency, the effect is remarkable.
京公网安备 11010502046598号